返回 $name
Session Chair(s)
Thomas Noto
Senior Director, Regulatory Operations
Lexicon Pharmaceuticals, United States
Learning Objective : -Overview of an original ANDA submission. -Distinguishing legal factors that make an ANDA first-to-file. -Identifying critical publishing standards to avoid receiving an RTR. -Identifying key miles stones when developing a project plan.
Speaker(s)
A Race to Submit: An Overview of Submitting First-To-File ANDAs
Ryan Hernandez
Radius Health, United States
Director of Regulatory Operations
FDA eSubmissions for Non-Commercial Research INDs – Tools, Problems, and Promise to Reduce the Paper Burden
Mitchell Seymour, PhD, RAC
Biohaven Pharmaceuticals, United States
Principal/Founder; Lead, Regulatory Operations
Integral Submission Lifecycle - A Holistic Approach to Comprehensively Manage CMC Submission Documents and Processes Globally
Romuald Braun, MS, MSc, RAC
Uanotau Gmbh, Switzerland
Managing Director